{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:18:43Z","timestamp":1763018323086,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19lk0201097h0001","20lk0201097h0002"],"award-info":[{"award-number":["19lk0201097h0001","20lk0201097h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The prophylactic use of anti-respiratory syncytial virus (RSV) antibody (palivizumab) for severe RSV infection is not approved in Japan in specified groups of infants with neuromuscular diseases or other rare diseases associated with reduced ventilation competence or difficulty in expectoration, which increase the risk of exacerbation of severe RSV infection. The objective of this study is to investigate the efficacy, safety, and pharmacokinetics of palivizumab in pediatric patients with those rare diseases for which palivizumab is not indicated at present.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>This study is a multicenter, uncontrolled, open-label study planned to be carried out between July 1, 2019 and June 30, 2022 at 7 medical institutions in Japan. The study population will be recruited from among neonates, infants, or children aged 24\u2009months or younger with a condition falling under any of the following 5 disease groups: pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, inherited metabolic disease, or neuromuscular disease. The planned sample size is 18 subjects, including at least 3 subjects per disease group. Throughout the RSV season, at least 4 continuous doses of palivizumab will be administered intramuscularly at 15\u2009mg\/kg at intervals of 30\u2009days. The efficacy and safety of palivizumab will be comprehensively evaluated based on the incidence of RSV-related hospitalization, and serum palivizumab concentration, serum anti-palivizumab antibody concentration, and the occurrence of adverse events\/reactions after the start of palivizumab treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will evaluate the efficacy and safety of palivizumab in pediatric patients with rare diseases which place them at high risk of severe RSV infection, but which fall outside the current indications for palivizumab prophylaxis. The generated data will have implications for the regulatory approval of prophylactic palivizumab treatment in this patient group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study has been prospectively registered in Japic Clinical Trials Information, which is managed and administered by the Japan Pharmaceutical Information Center (registration number: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.jp\/cti-user\/trial\/ShowDirect.jsp?japicId=JapicCTI-194946\">JapicCTI-194946<\/jats:ext-link>, registration date: September 10, 2019).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-021-02567-6","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T05:40:29Z","timestamp":1614663629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-4866","authenticated-orcid":false,"given":"Masaaki","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaya","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Ishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Tanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kusuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"2567_CR1","unstructured":"National Institute of Infectious Diseases Japan: RSV Infection, IDWR Issue No. 22 [https:\/\/www.niid.go.jp\/niid\/ja\/kansennohanashi\/317-rs-intro.html]. Last accessed on 4 Aug 2020, In Japanese."},{"issue":"5","key":"2567_CR2","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1086\/514115","volume":"176","author":"S Johnson","year":"1997","unstructured":"Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5):1215\u201324.","journal-title":"J Infect Dis"},{"issue":"3 Pt 1","key":"2567_CR3","first-page":"531","volume":"102","author":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","year":"1998","unstructured":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531\u20137.","journal-title":"Pediatrics"},{"key":"2567_CR4","unstructured":"AbbVie GK. Drug Interview Form Synagis\u00ae liquid 50 mg, 100 mg for Intramuscular Injection. https:\/\/druginfo.nlm.nih.gov\/drugportal\/."},{"issue":"4","key":"2567_CR5","first-page":"215","volume":"50","author":"Y Takeuchi","year":"2002","unstructured":"Takeuchi Y, Cho H, Yamashita Y, Mishiku Y, Nakao A, Aso T, Nishida H, Takahashi N, Sakuma I, Kawakami T, et al. Safety and pharmacokinetics of palivizumab administered in infants with a history of prematurity or chronic lung disease. J Jpn Soc Chemother. 2002;50(4):215\u201322 In Japanese with English abstract.","journal-title":"J Jpn Soc Chemother"},{"issue":"11","key":"2567_CR6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1097\/INF.0000000000000392","volume":"33","author":"M Mori","year":"2014","unstructured":"Mori M, Onodera M, Morimoto A, Kosaka Y, Morio T, Notario GF, Sharma S, Saji T. Palivizumab use in Japanese infants and children with immunocompromised conditions. Pediatr Infect Dis J. 2014;33(11):1183\u20135.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2567_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10156-010-0121-1","volume":"17","author":"M Mori","year":"2011","unstructured":"Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, Tsutsumi H, Yokota S, Itoh S. Surveillance Committee for Severe RSVI: Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother. 2011;17(2):254\u201363.","journal-title":"J Infect Chemother"},{"issue":"6","key":"2567_CR8","first-page":"1046","volume":"113","author":"M Mori","year":"2009","unstructured":"Mori M, Nakagawa M, Tsutsumi H, Kawashima N, Nakamura H, Kusuda S, Saji T, Yokota S, Itoh S. Analysis of nationwide survey of children requiring prevention of respiratory syncytial virus infection in Japan. J Jpn Pediatr Soc. 2009;113(6):1046\u20138 In Japanese.","journal-title":"J Jpn Pediatr Soc"},{"issue":"1","key":"2567_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40272-017-0264-y","volume":"20","author":"T Kashiwagi","year":"2018","unstructured":"Kashiwagi T, Okada Y, Nomoto K. Palivizumab prophylaxis against respiratory syncytial virus infection in children with Immunocompromised conditions or Down syndrome: a multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(1):97\u2013104.","journal-title":"Paediatr Drugs"},{"issue":"7","key":"2567_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/jp.2008.28","volume":"28","author":"M Frogel","year":"2008","unstructured":"Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M. Palivizumab outcomes registry G: prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab outcomes registry. J Perinatol. 2008;28(7):511\u20137.","journal-title":"J Perinatol"},{"issue":"6","key":"2567_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/INF.0b013e31805d01e3","volume":"26","author":"A Wilkesmann","year":"2007","unstructured":"Wilkesmann A, Ammann RA, Schildgen O, Eis-Hubinger AM, Muller A, Seidenberg J, Stephan V, Rieger C, Herting E, Wygold T, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007;26(6):485\u201391.","journal-title":"Pediatr Infect Dis J"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-021-02567-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12887-021-02567-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-021-02567-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T05:41:59Z","timestamp":1614663719000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-021-02567-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2567"],"URL":"https:\/\/doi.org\/10.1186\/s12887-021-02567-6","relation":{},"ISSN":["1471-2431"],"issn-type":[{"type":"electronic","value":"1471-2431"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study protocol was approved by the Institutional Review Board, Tokyo Medical and Dental University Hospital of Medicine. Ethical approval number: 2019\u20131001. Prior to the start of any study procedure, the investigator will create an informed consent form and written information that will be used to obtain consent to participate for prospective subjects in the study from their legally acceptable representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MM received research grants from AbbVie GK during the conduct of the study. AH received a personal fee from AbbVie GK not related to the study. The rest of the authors declare that they have no conflict of interests. Neither AbbVie GK nor AMED have any role in the design of the study; the collection, analysis, or interpretation of data; or in the decision to publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}